Terebellum Hosts Strategic Sessions on International Pharmaceutical Partnerships
Strategic planning sessions were recently hosted by the Terebellum team in Manchester, UK and Dublin, Ireland to focus on development of our international positioning in 2023.
The strategic planning sessions reviewed synergies underway with pharmaceutical company partners and plan management training programs. Collaborating with The Brooks Group, an organisation that deploys real science and real insights to deliver training that leads to increased sales and revenue, our leadership team articulated the groundwork for go-forward robust operations.
Craig Caceci, executive vice president and managing director, Terebellum, says, “We are bringing to the European marketplace our passionate commitment to provide innovative programs and services designed to optimise clinical outcomes and quality of life for patients with complex chronic conditions or rare diseases.
“Working with multiple pharmaceutical manufacturers to help them realise a product’s full potential, we provide a full complement of integrated solutions, including strategic insights for early-stage products, market access expertise, supply chain logistics distribution and fulfilment and unique pharmaceutical financial services.”
Caceci points to Terebellum’s commitment to always put patients first, adding, “This value statement transcends every aspect of our consultative approach to providing end-to-end solutions that result in better patient outcomes.
“This level of dedication distinguishes our organisation and contributes to our growing stature among pharmaceutical companies throughout the world that benefit from working with a single resource for managing all program and drug launch milestones.”
Instrumental in the planning sessions, John Bruton, former Taoiseach of Ireland and a non-executive resident director and board member, Terebellum, says, “Many people suffer from conditions that are so rare that cures have either not been developed, or are prohibitively expensive.
“I have become aware of this over many years. Terebellum attempts to resolve this problem through collaboration with patients, their families, pharmaceutical manufacturers and insurers.”